Thermidas for investors

Thermidas for investors

Series A coming soon

Diabetes is reaching pandemic levels, affecting half a billion people.

The treatment of Diabetic Foot Ulcers costs approximately $150 billion annually
  • Approximately 2% of diabetic patients will have a diabetic foot ulcer (DFU) at any given time
  • 80 % of lower extremity amputations (LEA’s) are preceded by a DFU
  • 50 % of DFU patients die within 5 years
  • 70 % of LEA patients die within 5 years

Number of adults with diabetes worldwide

A study by APMA found that among patients with commercial insurance, each $1 invested in care by a podiatrist results in $27 to $51 of savings for the health-care system. Among Medicare-eligible patients, each $1 invested in care by a podiatrist results in $9 to $13 of savings.

Solution:
Early detection with
Infrared Thermography

  • Extensive research shows skin breakdown takes place with persistent >2°C elevated temperature for up to 10 days

  • Up to 75 % of diabetic foot ulcers can be prevented by early detection

  • Up to 91 % of pre-ulcerous sites can be identified by the detection of temperature anomalies
  • People with normal physiological function will reflect thermal symmetry​
  • The same body area on the contralateral sides of the body will have similar temperatures​
  • Infrared Thermography will instantly highlight anomalies​

Market size

Diabetes is the #3 killer in USA after heart disease and cancer

530 million +

Diabetics worldwide

44% undiagnosed 
$966 bil. health expenditure
6.7 mil. deaths annually

Up to 34 %

Of diabetics develop a DFU (1)

40 % recurrence in one year (1)
20 % lead to amputation (2)

$13 billion

Cost of DFUs in the U.S. (3)

32 mil. total diabetics
4 mil. undiagnosed
$379 bil. health expenditure

£900 million

Cost of DFUs in the UK (4)

4 mil. total diabetics
0.9 mil. undiagnosed
$23 mil. health expenditure

(1) Armstrong, David G et al. “Diabetic Foot Ulcers and Their Recurrence.” (2017)
(2) McDermott, Katherine et al. “Etiology, Epidemiology, and Disparities in the Burden of Diabetic Foot Ulcers.” (2023)
(3) Rice, J Bradford et al. “Burden of diabetic foot ulcers for medicare and private insurers.” (2014)
(4) Kerr, M et al. “The cost of diabetic foot ulcers and amputations to the National Health Service in England.” (2019)
The rest: International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Brussels, Belgium: 2021. Available at: https://www.diabetesatlas.org

2008
Thermidas established
2016
First system sold

Oulu University Hospital acquired a Thermidas ThIR-A615 Thermal Imaging System

2017
Patent application

For Thermidas thermal imaging method

2018
CE-certificate in EU

Thermidas ThIR-A615 became the world's first medical CE-certified thermal imaging system.

2020
FDA 510k submission

Application sent for Thermidas Imager software

2021
FDA Clearance

FDA Clearance for Thermidas Imager software

2022
IRT-384 Tablet introduced

IRT-384 is an all-in-one solution for capturing and analyzing thermal images

2022
Patent granted

European patent for Thermidas thermal imaging method

2023
IRT-384 FDA

IRT-384 Tabled added to the FDA device listing

2023
UK: Telehealth NHS Clinical Trial

NHS started a pilot study with Thermidas Remote Monitoring Solution

2023
USA: Advent Health Clinical Study

Scaling beyond diabetic foot

20 + clinical studies conducted in university hospitals

  • Vascular Surgery
  • Plastic Surgery
  • Hand Surgery
  • Orthopaedics
  • Neurology/pain
  • Sports medicine